GammaTile^®: Surgically targeted radiation therapy for glioblastomas

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Heron M. Deaths: leading causes for 2017. Natl Vital Stat. Rep. 66(5), 1–76 (2019).
  Google Scholar
• 2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
  Medline CASGoogle Scholar
• 3. Ostrom QT, Gittleman H, Xu J et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro-oncology 18(Suppl. 5), v1–v75 (2016).
  MedlineGoogle Scholar
• 4. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
  Medline CASGoogle Scholar
• 5. Stupp R, Taillibert S, Kanner A et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23), 2306–2316 (2017). •• Demonstrates extension of overall survival with the use of tumor treating fields.
  Medline CASGoogle Scholar
• 6. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005).
  Medline CASGoogle Scholar
• 7. Ogura K, Mizowaki T, Arakawa Y et al. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat. Oncol. 8(1), 97 (2013).
  Medline CASGoogle Scholar
• 8. Gaspar LE, Fisher BJ, Macdonald DR et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biology Phys. 24(1), 55–57 (1992).
  Medline CASGoogle Scholar
• 9. Petrecca K, Guiot M-C, Panet-Raymond V, Souhami L. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J. Neurooncol. 111(1), 19–23 (2012).
  MedlineGoogle Scholar
• 10. Nagashima G, Suzuki R, Hokaku H et al. Graphic analysis of microscopic tumor cell infiltration, proliferative potential and vascular endothelial growth factor expression in an autopsy brain with glioblastoma. Surg. Neurol. 51(3), 292–299 (1999).
  Medline CASGoogle Scholar
• 11. Pirzkall A, McGue C, Saraswathy S et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro-oncology 11(6), 842–852 (2009).
  Medline CASGoogle Scholar
• 12. Pennington C, Kilbride L, Grant R, Wardlaw JM. A pilot study of brain tumour growth between radiotherapy planning and delivery. Clin. Oncol. 18(2), 104–108 (2006).
  CASGoogle Scholar
• 13. Waters JD, Rose B, Gonda DD et al. Immediate postoperative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. J. Neurooncol. 113(3), 467–477 (2013). •• Demonstrates safety of radioactive seed implantation in combination with adjuvant chemoradiation therapy as an outlook for possible future combination of different therapies.
  Medline CASGoogle Scholar
• 14. Buszek SM, Feghali KAA, Elhalawani H, Chevli N, Allen PK, Chung C. Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the National Cancer Database. Sci. Rep. 10(1), 4926 (2020).
  Medline CASGoogle Scholar
• 15. Han SJ, Rutledge WC, Molinaro AM et al. The effect of timing of concurrent chemoradiation in patients with newly diagnosed glioblastoma. Neurosurgery 77(2), 248–53 (2015).
  MedlineGoogle Scholar
• 16. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biology Phys. 16(6), 1405–1409 (1989).
  Medline CASGoogle Scholar
• 17. Sneed PK, Gutin PH, Larson DA et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int. J. Radiat. Oncol. Biology Phys. 29(4), 719–727 (1994).
  Medline CASGoogle Scholar
• 18. Wernicke AG, Yondorf MZ, Peng L et al. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J. Neurosurg. 121(2), 338–348 (2014).
  MedlineGoogle Scholar
• 19. Wernicke AG, Taube S, Smith AW, Parashar B. Central nervous system brachytherapy. In: Handbook of Image-Guided Brachytherapy. Mayadev JBenedict SKamrava M (Eds). Springer, Cham, Switzerland, 539–556 (2017).
  Google Scholar
• 20. Gupta VK. Brachytherapy – past, present and future. J. Med. Phys. 20, 31–38 (1995).
  Google Scholar
• 21. Jiang P, Geenen M, Siebert F-A et al. Efficacy and the toxicity of the interstitial high-dose-rate brachytherapy in the management of recurrent keloids: 5-year outcomes. Brachytherapy 17(3), 597–600 (2018).
  MedlineGoogle Scholar
• 22. Langley SEM, Laing RW. Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer. Prostate Cancer Prostatic Dis. 7(3), 201–207 (2004).
  Medline CASGoogle Scholar
• 23. Diener-West M, Earle JD, Fine SL et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. Arch. Ophthalmol. 119(7), 969 (2001).
  Medline CASGoogle Scholar
• 24. Henschke UK, Lawrence DC. Cesium-131 seeds for permanent implants. Radiology 85(6), 1117–1119 (1965).
  Medline CASGoogle Scholar
• 25. Chiu-Tsao S-T, Napoli JJ, Davis SD, Hanley J, Rivard MJ. Dosimetry for ¹³¹Cs and ¹²⁵I seeds in solid water phantom using radiochromic EBT film. Appl. Radiat. Isotopes 92, 102–114 (2014).
  Medline CASGoogle Scholar
• 26. Shrieve DC, Loeffler JS. Advances in radiation therapy for brain tumors. Neurol. Clin. 13(4), 773–793 (1995).
  Medline CASGoogle Scholar
• 27. Lodge WO. Treatment of intrasellar tumours by radon. BMJ 2(3963), 1257–1258 (1936).
  Medline CASGoogle Scholar
• 28. Gutin PH, Phillips TL, Hosobuchi Y et al. Permanent and removable implants for the brachytherapy of brain tumors. Int. J. Radiat. Oncol. Biology Phys. 7(10), 1371–1381 (1981).
  Medline CASGoogle Scholar
• 29. Prados M, Leibel S, Barnett CM, Gutin P. Interstitial brachytherapy for metastatic brain tumors. Cancer 63(4), 657–660 (1989).
  Medline CASGoogle Scholar
• 30. Ruge MI, Kocher M, Maarouf M et al. Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther. Onkol. 187(1), 7–14 (2010).
  MedlineGoogle Scholar
• 31. Petr MJ, McPherson CM, Breneman JC, Warnick RE. Management of newly diagnosed single brain metastasis with surgical resection and permanent I-125 seeds without upfront whole brain radiotherapy. J. Neurooncol. 92(3), 393–400 (2009).
  MedlineGoogle Scholar
• 32. Ruge MI, Suchorska B, Maarouf M et al. Stereotactic ¹²⁵iodine brachytherapy for the treatment of singular brain metastases: closing a gap? Neurosurgery 68(5), 1209–18 (2011).
  MedlineGoogle Scholar
• 33. Wernicke AG, Lazow SP, Taube S et al. Surgical technique and clinically relevant resection cavity dynamics following implantation of cesium-131 brachytherapy in patients with brain metastases. Oper. Neurosurg. 12(1), 49–60 (2015).
  MedlineGoogle Scholar
• 34. Han DY, Ma L, Braunstein S, Raleigh D, Sneed PK, McDermott M. Resection cavity contraction effects in the use of radioactive sources (1–25 versus Cs-131) for intra-operative brain implants. Cureus 10(1), e2079 (2018).
  MedlineGoogle Scholar
• 35. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int. J. Radiat. Oncol. Biology Phys. 55(2), 378–385 (2003).
  Medline CASGoogle Scholar
• 36. Murphy MK, Piper RK, Greenwood LR et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med. Phys. 31(6), 1529–1538 (2004).
  Medline CASGoogle Scholar
• 37. Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23(1), 27–30 (1988).
  Medline CASGoogle Scholar
• 38. Gutin PH, Leibel SA, Wara WM et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J. Neurosurg. 67(6), 864–873 (1987).
  Medline CASGoogle Scholar
• 39. Laperriere NJ, Leung PMK, McKenzie S et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int. J. Radiat. Oncol. Biology Phys. 41(5), 1005–1011 (1998).
  Medline CASGoogle Scholar
• 40. Selker RG, Shapiro WR, Burger P et al. The brain tumor cooperative group NIH trial 87-01: a randomized comparison of surgery, external radiotherapy and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy and carmustine. Neurosurgery 51(2), 343 (2002).
  MedlineGoogle Scholar
• 41. Ribas A, Hamid O, Daud A et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315(15), 1600 (2016).
  Medline CASGoogle Scholar
• 42. Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5(2), 79–88 (2003). • Suggests benefit of locally applied chemotherapy as a potential option.
  Medline CASGoogle Scholar
• 43. Siddiqi SN, Provias J, Laperriere N, Bernstein M. Effects of iodine-125 brachytherapy on the proliferative capacity and histopathological features of glioblastoma recurring after initial therapy. Neurosurgery 40(5), 910–918 (1997).
  Medline CASGoogle Scholar
• 44. Welsh J, Sanan A, Gabayan AJ et al. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int. J. Radiat. Oncol. Biology Phys. 68(1), 159–165 (2007).
  MedlineGoogle Scholar
• 45. Brachman DG, Youssef E, Dardis CJ et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J. Neurosurg. 131(6), 1819–1828 (2019).
  CASGoogle Scholar
• 46. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy 18(3), S35–S36 (2019). •• Study suggests potential benefit of GammaTile® for the treatment of several brain neoplasms.
  Google Scholar
• 47. Wernicke AG, Hirschfeld CB, Smith AW et al. Clinical outcomes of large brain metastases treated with neurosurgical resection and intraoperative cesium-131 brachytherapy: results of a prospective trial. Int. J. Radiat. Oncol. Biology Phys. 98(5), 1059–1068 (2017).
  MedlineGoogle Scholar
• 48. Wernicke AG, Smith AW, Taube S et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J. Neurosurg. 126(4), 1212–1219 (2017).
  Medline CASGoogle Scholar
• 49. Pham A, Yondorf MZ, Parashar B et al. Neurocognitive function and quality of life in patients with newly diagnosed brain metastasis after treatment with intra-operative cesium-131 brachytherapy: a prospective trial. J. Neurooncol. 127(1), 63–71 (2015).
  MedlineGoogle Scholar
• 50. Youssef E, Nakaji P, Thomas T, McBride H, Fram E, Brachman D. SCDT-36. Novel modular, permanently implanted collagen-based device for intraoperative brachytherapy in patients with central nervous system tumors. Neuro-oncology 19(Suppl. 6), vi272–vi272 (2017).
  Google Scholar
• 51. Rivard MJ. Brachytherapy dosimetry parameters calculated for a ¹³¹Cs source. Med. Phys. 34(2), 754–762 (2007).
  Medline CASGoogle Scholar
• 52. Chitti B, Goyal S, Sherman JH et al. The role of brachytherapy in the management of brain metastases: a systematic review. J. Contemp. Brachyther. 12(1), 67–83 (2020).
  MedlineGoogle Scholar
• 53. Vitaz TW, Warnke PC, Tabar V, Gutin PH. Brachytherapy for brain tumors. J. Neurooncol. 73(1), 71–86 (2005).
  MedlineGoogle Scholar
• 54. Ferreira C, Alaei P, Chen C, Reynolds M, Sterling D, Dusenbery K. RTHP-32. First experience with gammatile permanent implants for recurrent brain tumors. Neuro-oncology 21(Suppl. 6), vi216–vi216 (2019).
  Google Scholar
• 55. D P, S S, E Y et al. “Dosimetric impact of source migration and decay based on radioisotope type in collagen carrier brain brachytherapy implants”. Med. Phys. e244(45), (2018).
  Google Scholar
• 56. Ardizzone L, Barber T, Drebin J et al. Cancer surgery and COVID19. Ann. Surg. Oncol. 27(6), 1713–1716 (2020).
  MedlineGoogle Scholar
• 57. Raizer JJ, Fitzner KA, Jacobs DI et al. Economics of malignant gliomas: a critical review. J. Oncol. Pract. Am. Soc. Clin. Oncol. 11(1), e59–e65 (2014).
  Google Scholar
• 58. Yondorf MZ, Parashar B, Sabbas A et al. Radiation exposure after neurosurgical resection and permanent intraoperative cesium-131 radio-isotope brachytherapy in patients with brain tumors. Brachytherapy 13, S109–S110 (2014).
  Google Scholar
• 59. Champeaux C, Weller J. Implantation of carmustine wafers (Gliadel^®) for high-grade glioma treatment. A 9-year nationwide retrospective study. J. Neurooncol. 147(1), 159–169 (2020).
  MedlineGoogle Scholar
• 60. Ko A, Fink K, Stelzer K, Silbergeld D. Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma. Surg. Neurology Int. 3(1), 137 (2012).
  MedlineGoogle Scholar
• 61. Drumm MR, Dixit KS, Grimm S et al. Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-oncology 22(4), 470–479 (2020). • Highlights glioblastoma invasion of brain stem.
  MedlineGoogle Scholar
• 62. Chen AM, Chang S, Pouliot J et al. Phase I trial of gross total resection, permanent iodine-125 brachytherapy and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biology Phys. 69(3), 825–830 (2007).
  Medline CASGoogle Scholar
• 63. Archavlis E, Tselis N, Birn G, Ulrich P, Zamboglou N. Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation and chemotherapy. Neurol. Res. 36(12), 1047–1055 (2014).
  Medline CASGoogle Scholar